IRIS
D'AMICO, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.773
AS - Asia 2.838
EU - Europa 2.744
SA - Sud America 537
AF - Africa 490
Continente sconosciuto - Info sul continente non disponibili 239
OC - Oceania 10
Totale 12.631
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.569
SG - Singapore 1.504
RU - Federazione Russa 978
CN - Cina 686
IT - Italia 501
IE - Irlanda 441
BR - Brasile 423
CI - Costa d'Avorio 300
VN - Vietnam 258
UA - Ucraina 198
FR - Francia 159
CA - Canada 155
DE - Germania 105
KR - Corea 82
IN - India 81
GB - Regno Unito 77
NG - Nigeria 65
NL - Olanda 65
BD - Bangladesh 62
SE - Svezia 59
SN - Senegal 56
AR - Argentina 35
PL - Polonia 30
FI - Finlandia 29
ZA - Sudafrica 28
IQ - Iraq 24
MX - Messico 21
VE - Venezuela 20
CH - Svizzera 19
UZ - Uzbekistan 19
EC - Ecuador 18
TR - Turchia 17
HK - Hong Kong 16
PK - Pakistan 13
CO - Colombia 12
ES - Italia 12
JP - Giappone 12
AT - Austria 11
EG - Egitto 9
JM - Giamaica 9
SA - Arabia Saudita 9
AU - Australia 8
LB - Libano 8
LT - Lituania 8
MA - Marocco 8
PY - Paraguay 8
CL - Cile 7
HR - Croazia 7
KE - Kenya 7
AZ - Azerbaigian 6
BE - Belgio 6
PE - Perù 6
BJ - Benin 5
CR - Costa Rica 5
CZ - Repubblica Ceca 5
DZ - Algeria 5
GR - Grecia 5
HU - Ungheria 5
ID - Indonesia 5
JO - Giordania 5
NP - Nepal 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
IL - Israele 4
RO - Romania 4
RS - Serbia 4
UY - Uruguay 4
BG - Bulgaria 3
IR - Iran 3
LK - Sri Lanka 3
PS - Palestinian Territory 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
CG - Congo 2
GT - Guatemala 2
KH - Cambogia 2
LU - Lussemburgo 2
LV - Lettonia 2
MD - Moldavia 2
NI - Nicaragua 2
PA - Panama 2
PH - Filippine 2
BT - Bhutan 1
BY - Bielorussia 1
DM - Dominica 1
EU - Europa 1
KG - Kirghizistan 1
KI - Kiribati 1
KN - Saint Kitts e Nevis 1
MT - Malta 1
MY - Malesia 1
OM - Oman 1
PT - Portogallo 1
PW - Palau 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 12.391
Salva come PNG Salva come JPEG
Città #
Singapore 895
Dallas 853
Santa Clara 677
Chandler 562
Moscow 450
Dublin 438
San Jose 391
Ashburn 337
Abidjan 300
Chicago 207
Jacksonville 196
Boardman 181
Council Bluffs 173
Cambridge 119
Lawrence 119
Houston 118
Andover 116
Los Angeles 114
Lauterbourg 112
Nanjing 101
Beijing 96
Toronto 84
Seoul 82
Catania 80
Hefei 75
Ho Chi Minh City 70
Civitanova Marche 63
Des Moines 57
Dakar 56
Hanoi 53
Wilmington 49
Amsterdam 43
New York 38
São Paulo 35
Nanchang 34
Grafing 33
Lagos 33
Shenyang 32
Bremen 31
Buffalo 30
Ottawa 29
San Mateo 29
Saint Petersburg 28
Columbus 26
Dong Ket 26
Abuja 25
The Dalles 23
Changsha 22
Hebei 22
Orem 22
Lappeenranta 20
Rome 20
Jiaxing 19
San Francisco 19
Warsaw 19
Bari 18
Montreal 18
Denver 17
London 17
Washington 17
Tianjin 16
Chennai 15
Johannesburg 15
Phoenix 14
Mumbai 13
Da Nang 12
Milan 12
Seattle 12
Hong Kong 11
Rio de Janeiro 11
Siracusa 11
Stockholm 11
Tokyo 11
Jinan 10
Naples 10
Poplar 10
Pune 10
Quito 10
Tashkent 10
Belo Horizonte 9
Dhaka 9
Elk Grove Village 9
Frankfurt am Main 9
Haiphong 9
Norwalk 9
Padova 9
Palermo 9
Zhengzhou 9
Baghdad 8
Brasília 8
Charlotte 8
Helsinki 8
Kunming 8
Manchester 8
Ningbo 8
Redondo Beach 8
Ann Arbor 7
Brooklyn 7
Den Haag 7
Guarulhos 7
Totale 8.366
Salva come PNG Salva come JPEG
Nome #
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 213
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 188
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 175
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 173
Management of dysphagia in multiple sclerosis: current best practice 162
Comparison of genioglossus muscle activity and efficiency of dexmedetomidine or propofol during drug-induced sleep endoscopy in patients with obstructive sleep apnea/hypopnea syndrome 161
An update on the safety of treating relapsing-remitting multiple sclerosis 155
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 154
An update on the pharmacological management of pain in patients with multiple sclerosis 149
Cognitive impairment and "invisible symptoms" are not associated with CCSVI in MS 146
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 142
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 138
CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset 138
Association between dietary intake and function in amyotrophic lateral sclerosis 137
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 135
Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study 134
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 134
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 133
Can new chemical therapies improve the management of multiple sclerosis in children? 133
Approccio clinico e possibilità di trattamento nella SLA 131
CCSVI and MS. A population-based case-control study in Catania, Sicily. 130
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 129
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. 128
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 126
Post-Cerebrovascular Stroke and Early Dysphagia Assessment: A Systematic Review 125
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 124
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 120
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 118
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 118
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 118
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life 116
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 115
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 115
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 115
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 115
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 114
Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis 114
Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla 114
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 113
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 112
Depressive symptoms correlate with disability and disease course in multiple sclerosis patients: An Italian multi-center study using the Beck Depression Inventory 112
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 112
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 112
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. 111
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 107
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 107
Primary cerebral vasculitis 106
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion 106
Pharmacoeconomics of synthetic therapies for multiple sclerosis 106
Toxoplasma gondii and multiple sclerosis: a population-based case–control study 106
Wegener’s Granulomatosis Presenting as An Intracranial Hypertension Syndrome Treated with High Dose of Cyclophosphamide 105
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 104
Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria 104
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 104
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 102
Oral drugs in multiple sclerosis therapy: An overview and a critical appraisal 101
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 101
Palliative care in progressive multiple sclerosis 99
Multidisciplinary approach of amyotrophic lateral sclerosis: a centre experience 99
Cognitive impairment in clinical isolated syndrome suggestive of multiple sclerosis: association with brain imaging and retinal nerve fiber layer thickness 97
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 96
Offspring Number Does Not Influence Reaching the Disability's Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study 94
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 93
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 92
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study) 90
Detrimental effects of cyclophosphamide on seminal cells in men whith MS 90
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 89
Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 88
Metal/metalloid levels in cerebrospinal fluid in the bulbar-and spinal-onset amyotrophic lateral sclerosis 87
Treatment options of cognitive impairment in multiple sclerosis 86
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 86
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 85
The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study 85
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 85
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 84
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 84
Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 84
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 83
Multiple Sclerosis and CCSVI: A Population-Based Case Control Study 83
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience 82
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 79
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 78
Conventional brain MRI could be a predictor of post partum relapse in multiple sclerosis 78
Gender related thyroid dysfunction and autoimmunità in multiple sclerosis patients treated with interferon-beta 78
Cognitive-motor dual-task interference:A systematic review of neural correlates 78
Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial 78
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 77
Genetic burden of common variants in progressive and bout-onset multiple sclerosis 77
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis 76
Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods 76
Prevalence of patient-reported disphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire) 75
The effects of different cognitive and motor tasks on the dual task cost of walking in multiple sclerosis: a case-control study 75
Negative prognostic impact of MRI spinal lesion in the early stages of relapsing-remitting multiple sclerosis 73
Prevalence of pain in multiple sclerosis: a multicenter italian study 72
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 72
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 72
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question 72
Treatment in worsening multiple sclerosis patients: new drugs are better than older ones? 71
Untreated relapsing remitting multiple sclerosis (RR-MS) patients. A single centre exprerience 71
Real-World comparison of reasons for changing treatment to dimethyl-fymarate or teriflunomide in non responders patients with relapsing remitting multiple sclerosis: preliminary results of a multicenter prospective study 69
Totale 10.754
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.834
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.834
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022720 0 130 15 8 125 4 123 22 52 5 41 195
2022/20231.609 128 84 30 164 154 282 4 281 386 6 68 22
2023/2024704 34 182 37 19 23 119 21 64 4 31 117 53
2024/20252.438 30 366 150 128 493 354 75 94 198 231 172 147
2025/20265.462 305 214 981 371 835 1.070 661 124 261 352 159 129
2026/2027257 102 155 0 0 0 0 0 0 0 0 0 0
Totale 12.631